Teratology: Causes, Principles, and Prenatal Diagnosis
This paper provides a structured overview of teratology, the study of abnormal fetal growth. It defines teratology and outlines the major categories of congenital abnormalities, including malformations, deformations, and disruptions. A detailed reference table catalogues the fetal and maternal risks associated with a wide range of teratogenic agents — from prescribed drugs and environmental chemicals to infectious agents. The paper then articulates the six core principles of teratology, explaining how factors such as genotype, developmental timing, dosage, and agent access determine teratogenic outcomes. Hereditary causes of congenital malformations — including chromosomal aberrations, monogenic inheritance, and multifactorial inheritance — are also examined. Finally, the paper surveys both invasive and noninvasive prenatal diagnostic procedures used to identify congenital anomalies.
- Introduction to Teratology: Definition and categories of congenital abnormalities
- Effects of Teratogens During Different Periods of Development: Teratogenic agents, risks, and fetal effects by drug class
- Principles of Teratology: Six core principles governing teratogenic outcomes
- Hereditary Causes of Congenital Malformations: Genetic inheritance patterns and chromosomal causes
- Prenatal Diagnostic Procedures for Identifying Congenital Anomalies: Invasive and noninvasive prenatal diagnostic techniques
- Conclusion: Summary integrating teratology causes and diagnostic approaches
✍️ How to write this paper — guide, tools & examples ▾
What makes this paper effective
- The paper integrates a detailed comparative table of teratogenic agents with principled theoretical frameworks, giving readers both practical reference material and conceptual grounding.
- Each of the six teratology principles is stated clearly and supported with citations, demonstrating an ability to translate scientific literature into organized academic prose.
- The transition from causes (teratogens and hereditary factors) to diagnostic procedures gives the paper a logical clinical arc that mirrors real-world medical reasoning.
Key academic technique demonstrated
The paper demonstrates effective use of classification as an organizational strategy. By dividing congenital abnormalities into malformations, deformations, and disruptions, and then separately classifying teratogenic agents, inheritance patterns, and diagnostic methods, the author consistently uses taxonomic structure to manage complex biomedical information. This approach makes dense content accessible and reflects standard practice in medical and embryological writing.
Structure breakdown
The paper opens with a definition and classification of congenital abnormalities, followed by a reference table of teratogenic agents with associated fetal and maternal risks. The core theoretical section enumerates and explains six established principles of teratology. The hereditary causes section addresses genetic mechanisms including chromosomal, monogenic, and multifactorial inheritance. The paper closes with a survey of prenatal diagnostic techniques, distinguishing between invasive and noninvasive methods.
Introduction to Teratology
Teratology refers to the study of abnormal fetal growth. Teratogenic prenatal exposures arise from infectious agents, chemical and drug agents, metabolic or maternal causes (such as phenylketonuria and diabetes), and physical agents (such as heat, ionizing radiation, and mechanical factors) (Jelinek, 2005). Inborn abnormalities occur commonly: 2–3% of babies — both live and stillborn, as well as aborted fetuses — have structural abnormalities. Furthermore, about 10% of infants have internal functional deficits or anomalies that might not be perceptible at birth and may only surface later in life.
Congenital abnormalities can be categorized into three types: (1) Malformations, which denote changes in normal growth arising from an inherent developmental-process abnormality; (2) Deformations, which arise due to an irregular mechanical force upon an otherwise normal fetus (e.g., clubfoot in an environment of oligohydramnios); and (3) Disruptions, occurring because of a disturbance in the normal process of growth (for instance, gastroschisis, considered to be caused by vascular disturbance in the frontal abdominal wall of the fetus) (Adam, Polifka & Friedman, 2011).
Effects of Teratogens During Different Periods of Development
The following table summarizes major teratogenic agents, their risk categories, and their associated fetal and maternal effects across different periods of development (adopted from Wilson, 2007).
Prescribed or Illegal Drugs
Ethanol (Risk category: D/X). Fetal effects include Fetal Alcohol Effects (FAEs): microcephaly, intrauterine growth retardation (IUGR), mental retardation (MR), characteristic facies, and dermal, skeletal, joint, and congenital heart disease (CHD) abnormalities. There is a 40% risk associated with six drinks per day.
Cocaine (Risk category: C/X). Fetal effects include IUGR, bowel atresia, cerebral infarction, and vascular, heart, facial, limb, and genitourinary tract disruption. Fetal risks include fetal death; maternal risks include placental abruption.
Toluene (Risk category: X). Causes toluene embryopathy, which is similar to Fetal Alcohol Syndrome. Risk is 10–100 times higher with inhalation by the mother through occupational exposure.
Antimicrobial Agents
Tetracycline (Risk category: D). Causes deciduous teeth discoloration and enamel hypoplasia. Risk is greatest during the second and third trimesters.
Streptomycin (Risk category: Dm). Causes rare hearing loss with prolonged exposure at high doses. Risk is mainly during the second and third trimesters.
Fluconazole (Risk category: Cm). Associated with cleft palate, brachycephaly, CHD, and arthrogryposis. Risk is during the first trimester, particularly at high doses used for coccidioidomycosis treatment.
Trimethoprim-sulfamethoxazole. Associated with impaired conjugation of bilirubin. Risk is during the third trimester.
Anticancer Agents
Folic Acid Antagonists (Risk category: Xm). Associated with increased spontaneous abortion, stillbirth, ectrodactyly, skeletal abnormalities, craniofacial abnormalities, limb reduction deformities, neonatal death, and IUGR. There is a 30% risk if exposure occurs in the first trimester (methotrexate), with a possible increased risk when exposed during the first trimester (aminopterin).
Alkylating Agents (Risk category: Dm). Associated with IUGR, cleft palate, microphthalmia, genitourinary anomalies, and limb reduction deformities (e.g., busulfan).
Anticonvulsants
Phenytoin/Hydantoin (Risk category: D). Associated with MR, microcephaly, IUGR, heart and facial anomalies, hypoplastic distal phalanges/nails, and increased risk of neuroblastoma. There is a 30% exposure effect and 10% syndrome rate. Genetic makeup impacts metabolism.
Carbamazepine (Risk category: Dm). Associated with lumbosacral neural tube defect (1%), microcephaly, facial and nail hypoplasia, developmental delay, and IUGR. Risk is from first-trimester exposure.
Valproic acid (Risk category: Dm). Associated with lumbosacral neural tube defect (1%) and likely fetal valproate syndrome. Risk is from first-trimester exposure; the mother's drug metabolism alters the level of risk.
Trimethadione/Paramethadione (Risk category: D/Dm). Associated with IUGR, cleft lip with or without cleft palate, mental retardation, microcephaly, facial, limb, ophthalmologic, and genitourinary abnormalities. Risk is 60–80% with exposure during the first trimester.
Antihypertensive Agents
ACE inhibitors — enalapril, captopril, lisinopril (Risk category: Cm/Dm). Associated with IUGR, oligohydramnios, pulmonary hypoplasia, renal tubular dysplasia, joint contractures (30%), and fetal morbidity. Risk is increased with exposure during the second and third trimesters.
Heavy Metals and Environmental Agents
Lead. Associated with reduced fetal growth and an increased risk of spontaneous abortion.
Organic mercury. Associated with MR, cerebral atrophy, spasticity, microcephaly, blindness, and seizures. Exposure during any trimester poses a risk.
PCBs (polychlorinated biphenyls). Associated with intrauterine development restriction, retarded development, and dermal pigmentation. Maternal neurotoxicity is linked to grain and fish contamination.
Psychiatric Medications
Lithium (Risk category: D). Associated with neonatal CHD (Ebstein anomaly) and increased neuromuscular and central nervous system (CNS) complications.
SSRIs (Risk category: Cm/D for paroxetine). A benefit/risk analysis with an advisory recommendation applies. Paroxetine carries approximately 2% cardiac malformation risk. Small, variable fetal effects are noted; no risk has been conclusively proven for all SSRIs.
Tricyclic antidepressants (Risk category: D) and Bupropion (Risk category: Bm). Variable fetal effects noted.
Miscellaneous Agents
Methylene blue (Risk category: Cm/D). Intraamniotic exposure is linked to probable bowel atresia. Risk is dose-dependent.
Warfarin/Coumadin (Risk category: D/X). Associated with microtia, cardiac abnormalities, microphthalmia, nasal hypoplasia, craniofacial anomalies, cleft lip with or without cleft palate, IUGR, stippled epiphyses, CNS and ophthalmologic defects, and growth retardation. There is a 5–25% risk with first-trimester exposure.
Infectious Agents
Syphilis (bacterial). Severe cases may result in fetal death or hydrops. Milder cases affect bone, skin, or teeth. Neonatal effects include rash, rhinitis, pneumonia, thrombocytopenia, and liver dysfunction. Early penicillin therapy prevents congenital infection, though diagnosis and therapy are complex.
Rubella (viral). Associated with deafness, microcephaly, CHD, MR, and cataracts. Some deficits may not be apparent in the neonatal stage. Risk is approximately 50% with primary infection in the first trimester and 6% in the second trimester.
Principles of Teratology
Principle 1: Teratogenesis susceptibility is dependent on the conceptus genotype and its interaction with the environment. Taking into account established facts regarding the impact of known teratogen exposure, two of the most significant teratogen characteristics are: variable phenotype production in infants who are exposed and affected; and variable susceptibility, since exposure does not necessarily mean the infant will be affected (Finnell, 1999).
Principle 2: Teratogen susceptibility depends upon the stage of fetal development at which exposure takes place. A fundamental biological principle is that organisms in a developmental state are more susceptible to change than full-grown, mature organisms. Heightened susceptibility persists throughout the embryo's development, though the degree of susceptibility may vary (Finnell, 1999; Sadler, 2012).
Principle 3: Teratogens act through specific mechanisms on developing tissues and cells, giving rise to abnormal embryogenesis or pathogenesis. They typically represent the foremost event in a succession of intermediate events occurring between cause and effect. This first event is the most crucial in the series, as it links cause with subsequent physiologic changes and likely influences the nature of those changes (Finnell, 1999).
Principle 4: Abnormal growth eventually manifests as functional disorder, growth delay, death, or malformation. These likely outcomes of irregular fetal development do not occur with equal probability and are most likely linked to the timing of exposure in relation to embryonic development. Although one or all of these results may occur through exposure to sufficient levels of fetotoxic agents during high-sensitivity periods, certain manifestations are more likely at certain stages of development (Finnell, 1999; Sadler, 2012).
Principle 5: A harmful environmental agent's access to embryonic tissues depends on the agent's nature. Not every teratogen reaches the fetus in the same way. Ultrasound, microwaves, X-rays, and similar physical agents pass unchanged into the mother's uterus and directly reach the embryo. Ingested agents, such as drugs, are first subject to the mother's metabolism, and their fetal access is secondary. Consequently, drugs or chemicals typically reach the developing fetus in smaller concentrations than their original concentration in the mother's body. Whether that concentration is sufficient to cause harm depends on several factors (Finnell, 1999).
Principle 6: Abnormal developmental manifestations increase with dosage, from no-effect level to lethal level. As with medications and their curative effects, there is a dose-response relationship in teratogen activity. Consideration of this principle is essential, as it establishes the thresholds for different toxicologic outcomes (Finnell, 1999; Sadler, 2012).
Conclusion
Teratology encompasses a broad spectrum of influences on fetal development, from chemical and infectious teratogens to inherited genetic factors. Understanding these causes alongside the six core principles of teratogenesis equips clinicians and researchers to better identify risks and apply appropriate prenatal diagnostic strategies. The array of available diagnostic tools — ranging from amniocentesis and CVS to ultrasound and MRI — enables increasingly early and accurate identification of congenital anomalies, supporting timely clinical decision-making and genetic counseling.
References
Adam, M.P., Polifka, J.E. & Friedman, J.M. (2011). Evolving knowledge of the teratogenicity of medications in human pregnancy. Am J Med Genet C Semin Med Genet, 157C, 175.
Finnell, R.H. (1999). Teratology: General considerations and principles. J Allergy Clin Immunol, 103(2), S337–S342.
Jelinek, R. (2005). The contribution of new findings and ideas to the old principles of teratology. Reproductive Toxicology, 20, 295–300.
Jones, K.L. (2005). Smith's Recognizable Patterns of Human Malformation (6th ed.). Saunders.
Sadler, T.W. (2012). Langman's Medical Embryology. Wolters Kluwer/Lippincott Williams & Wilkins.
Shenoy, R.K. (2004). Bilateral congenital split hand with tibial aplasia. Indian J Pediatr, 71(10), 948.
Wilson, R.D. (2007). Principles of human teratology: Drug, chemical, and infectious exposure. J Obstet Gynaecol Can, 29(11), 911–917.
Create your account
Always verify citation format against your institution’s current style guide requirements.